These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

969 related articles for article (PubMed ID: 28059578)

  • 1. A Bayesian meta-analytic approach for safety signal detection in randomized clinical trials.
    Odani M; Fukimbara S; Sato T
    Clin Trials; 2017 Apr; 14(2):192-200. PubMed ID: 28059578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bayesian hierarchical model for safety signal detection in multiple clinical trials.
    Zhang Y; Yuan SS; Eagel BA; Li H; Lin LA; Wang WWB
    Contemp Clin Trials; 2020 Dec; 99():106183. PubMed ID: 33091588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian group sequential approach to safety signal detection.
    Chen W; Zhao N; Qin G; Chen J
    J Biopharm Stat; 2013; 23(1):213-30. PubMed ID: 23331232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
    Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
    Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Meta-analysis of the Italian studies on short-term effects of air pollution].
    Biggeri A; Bellini P; Terracini B;
    Epidemiol Prev; 2001; 25(2 Suppl):1-71. PubMed ID: 11515188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bayesian basket trial design using a calibrated Bayesian hierarchical model.
    Chu Y; Yuan Y
    Clin Trials; 2018 Apr; 15(2):149-158. PubMed ID: 29499621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the incidence and severity of drug adverse events: a Bayesian hierarchical cumulative logit model.
    Duan J; Gajewski BJ; Sen P; Wick JA
    J Biopharm Stat; 2024 Mar; 34(2):276-295. PubMed ID: 37016726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian hierarchical modeling for detecting safety signals in clinical trials.
    Xia HA; Ma H; Carlin BP
    J Biopharm Stat; 2011 Sep; 21(5):1006-29. PubMed ID: 21830928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
    Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
    J Urol; 2013 Jan; 189(1 Suppl):S135-40. PubMed ID: 23234619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis.
    Dong Y; Hao L; Shi Z; Wang G; Zhang Z; Han C
    Urol Int; 2013; 91(1):10-8. PubMed ID: 23816815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bayesian adjusted R2 for the meta-analytic evaluation of surrogate time-to-event endpoints in clinical trials.
    Renfro LA; Shi Q; Sargent DJ; Carlin BP
    Stat Med; 2012 Apr; 31(8):743-61. PubMed ID: 22161275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials.
    Sharma T; Gøtzsche PC; Kuss O
    J Clin Epidemiol; 2017 Nov; 91():129-136. PubMed ID: 28802674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian methods for design and analysis of safety trials.
    Price KL; Xia HA; Lakshminarayanan M; Madigan D; Manner D; Scott J; Stamey JD; Thompson L
    Pharm Stat; 2014; 13(1):13-24. PubMed ID: 23897858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of rare adverse events in randomized clinical trials: Bayesian and frequentist methods.
    Hong H; Wang C; Rosner GL
    Clin Trials; 2021 Feb; 18(1):3-16. PubMed ID: 33258698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust meta-analytic-predictive priors in clinical trials with historical control information.
    Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
    Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zero-Inflated Binomial Model for Meta-Analysis and Safety-Signal Detection.
    Chakraborty A; Xu J; Tiwari R
    Ther Innov Regul Sci; 2022 Mar; 56(2):255-262. PubMed ID: 35064554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence synthesis from aggregate recurrent event data for clinical trial design and analysis.
    Holzhauer B; Wang C; Schmidli H
    Stat Med; 2018 Mar; 37(6):867-882. PubMed ID: 29152777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Problematic meta-analyses: Bayesian and frequentist perspectives on combining randomized controlled trials and non-randomized studies.
    Moran JL; Linden A
    BMC Med Res Methodol; 2024 Apr; 24(1):99. PubMed ID: 38678213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Criteria revision and performance comparison of three methods of signal detection applied to the spontaneous reporting database of a pharmaceutical manufacturer.
    Matsushita Y; Kuroda Y; Niwa S; Sonehara S; Hamada C; Yoshimura I
    Drug Saf; 2007; 30(8):715-26. PubMed ID: 17696584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An alternative parameterization of Bayesian logistic hierarchical models for mixed treatment comparisons.
    Pechlivanoglou P; Abegaz F; Postma MJ; Wit E
    Pharm Stat; 2015; 14(4):322-31. PubMed ID: 25958984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.